• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SUD
Click for more information
0.00% 4.2¢

SUDA PHARMACEUTICALS LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SUD Annual Report to shareholders22/09/17
SUD Appendix 4G and Corporate Governance Statement22/09/17
SUD SUDA Publishes Amended Shareholder NewsletterPRICE SENSITIVE12/09/17
SUD Shareholder newsletter12/09/17
SUD Preliminary Final ReportPRICE SENSITIVE31/08/17
SUD Chairman's letter28/08/17
SUD SUDA announces new media article23/08/17
SUD Investor presentation15/08/17
SUD New analyst report15/08/17
SUD SUDA Achieves ISO AccreditationPRICE SENSITIVE31/07/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE27/07/17
SUD Strong Revenue Growth for SUDA SubsidiaryPRICE SENSITIVE24/07/17
SUD SUDA Announces New Flash Note06/07/17
SUD SUDA Enters Licence Agreement With TevaPRICE SENSITIVE05/07/17
SUD Trading HaltPRICE SENSITIVE04/07/17
SUD SUDA Signs Term Sheet To Acquire Anti-Cancer AgentPRICE SENSITIVE20/06/17
SUD Change of Director's Interest Notice07/06/17
SUD Appendix 3B02/06/17
SUD SUDA Meeting For Zolpimist Into EuropePRICE SENSITIVE25/05/17
SUD Change of Director's Interest Notice23/05/17
SUD Appendix 3B27/04/17
SUD Placement, Interest Shares and Convertible Note ProspectusPRICE SENSITIVE24/04/17
SUD Appendix 4C - quarterlyPRICE SENSITIVE19/04/17
SUD SUDA Completes $1.5m Capital RaisingPRICE SENSITIVE07/04/17
SUD Appendix 3B and Notice Under Section 708A06/04/17
SUD Trading HaltPRICE SENSITIVE05/04/17
SUD SUDA Submits Application For ArTiMistPRICE SENSITIVE03/04/17
SUD SUDA Extends Maturity of Convertible NotesPRICE SENSITIVE03/04/17
SUD SUDA Enters Feasibility Agreement With PfizerPRICE SENSITIVE29/03/17
SUD SUDA expands patent coverage for SUD-003 and SUD-004PRICE SENSITIVE03/03/17
SUD SUDA Announces Strong Revenue For WestcoastPRICE SENSITIVE27/02/17
SUD Half Yearly Report and AccountsPRICE SENSITIVE27/02/17
SUD Reinstatement to official quotationPRICE SENSITIVE27/02/17
SUD SUDA Update On Discussions with Berlin PharmaPRICE SENSITIVE27/02/17
SUD Company Update Regarding Suspension20/02/17
SUD SUDA receives $0.9m R&D tax incentive refund16/02/17
SUD Company Update Regarding Suspension10/02/17
SUD Appendix 4C - quarterly01/02/17
SUD Suspension from official quotationPRICE SENSITIVE27/01/17
SUD Trading HaltPRICE SENSITIVE24/01/17
SUD BRR Audio Webcast01/12/16
SUD Results of Meeting25/11/16
SUD AGM presentation25/11/16
SUD SUDA presents data on novel technologyPRICE SENSITIVE17/11/16
SUD SUDA Enters Licensing Agreement For ZolpiMist in ChinaPRICE SENSITIVE09/11/16
SUD Technology patent application-SUD.AX PRICE SENSITIVE02/11/16
SUD Ceasing to be a substantial holder-SUD.AX 01/11/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE31/10/16
SUD Notice of Annual General Meeting/Proxy Form-SUD.AX 21/10/16
SUD Appendix 3B-SUD.AX 05/10/16
SUD Appendix 4G and Corporate Governance Statement-SUD.AX 22/09/16
SUD Annual Report to shareholders-SUD.AX 22/09/16
SUD Investor Road Show Presentation-SUD.AX 20/09/16
SUD Letter to Shareholders-SUD.AX 13/09/16
SUD Preliminary Final Report-SUD.AX PRICE SENSITIVE31/08/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE29/07/16
SUD Analyst Report-SUD.AX 14/06/16
SUD Shareholder Update-SUD.AX 07/06/16
SUD Update on HC Berlin Pharma-SUD.AX PRICE SENSITIVE03/06/16
SUD Investor presentation-SUD.AX 03/05/16
SUD Appendix 4C - quarterly-SUD.AX PRICE SENSITIVE29/04/16
SUD Change of Director's Interest Notice-SUD.AX 28/04/16
SUD Business development update-SUD.AX PRICE SENSITIVE19/04/16
SUD SUDA granted Canadian Patent for SUD-002-SUD.AX PRICE SENSITIVE12/04/16
SUD Appendix 3B and Notice Under Section 708A-SUD.AX 04/04/16
SUD Appendix 3B08/03/16
SUD Half Yearly Report and Accounts (including Appendix 4D)PRICE SENSITIVE26/02/16
SUD SUDA Ltd investor presentation25/02/16
SUD SUDA featured in Business Review Australia11/02/16
SUD SUDA Ltd announces new analyst coverage09/02/16
SUD SUDA LTD Shareholder Update08/02/16
SUD SUDA receives $0.7m R&D tax incentive refundPRICE SENSITIVE05/02/16
SUD Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
SUD Change of Director's Interest Notice18/12/15
SUD Appendix 3B18/12/15
SUD SUDA amends agreement with Amherst PharmaceuticalsPRICE SENSITIVE10/12/15
SUD Response to Price Query LetterPRICE SENSITIVE07/12/15
SUD Becoming a substantial holder24/11/15
SUD Results of Meeting17/11/15
SUD AGM Presentation17/11/15
SUD SUDA LTD BUSINESS DEVELOPMENT UPDATE17/11/15
SUD Ceasing to be a substantial holder12/11/15
SUD SUDA Invited To Northern Australia Investment Forum03/11/15
SUD Appendix 4C - quarterlyPRICE SENSITIVE30/10/15
SUD Hong Kong Presentations29/10/15
SUD SUDA to present at Hong Kong investor showcase26/10/15
SUD Update on 2013 Convertible Notes and Appendix 3Y21/10/15
SUD Notice of Annual General Meeting/Proxy Form16/10/15
SUD SUDA LTD Audio Webcast16/10/15
SUD Letter to Shareholders15/10/15
SUD Update on Convertible Notes and Appendix 3B09/10/15
SUD SUDA allowed first USA patent for SUD-003 and SUD-004PRICE SENSITIVE08/10/15
SUD SUDA releases video from Singapore investor showcase05/10/15
SUD Annual Report to shareholders30/09/15
SUD Appendix 4G and Corporate Governance Statement30/09/15
SUD Appendix 3B and Notice Under Section 708A02/09/15
SUD Preliminary Final ReportPRICE SENSITIVE31/08/15
SUD SUDA announces ArTiMist clinical publicationPRICE SENSITIVE27/08/15
SUD SUDA takes full control of ArTiMistPRICE SENSITIVE26/08/15
SUD SUDA investor initiative and presentation14/08/15
SUD Annual Report to shareholders
22/09/17
SUD Appendix 4G and Corporate Governance Statement
22/09/17
SUD SUDA Publishes Amended Shareholder Newsletter
12/09/17PRICE SENSITIVE
SUD Shareholder newsletter
12/09/17
SUD Preliminary Final Report
31/08/17PRICE SENSITIVE
SUD Chairman's letter
28/08/17
SUD SUDA announces new media article
23/08/17
SUD Investor presentation
15/08/17
SUD New analyst report
15/08/17
SUD SUDA Achieves ISO Accreditation
31/07/17PRICE SENSITIVE
SUD Appendix 4C - quarterly
27/07/17PRICE SENSITIVE
SUD Strong Revenue Growth for SUDA Subsidiary
24/07/17PRICE SENSITIVE
SUD SUDA Announces New Flash Note
06/07/17
SUD SUDA Enters Licence Agreement With Teva
05/07/17PRICE SENSITIVE
SUD Trading Halt
04/07/17PRICE SENSITIVE
SUD SUDA Signs Term Sheet To Acquire Anti-Cancer Agent
20/06/17PRICE SENSITIVE
SUD Change of Director's Interest Notice
07/06/17
SUD Appendix 3B
02/06/17
SUD SUDA Meeting For Zolpimist Into Europe
25/05/17PRICE SENSITIVE
SUD Change of Director's Interest Notice
23/05/17
SUD Appendix 3B
27/04/17
SUD Placement, Interest Shares and Convertible Note Prospectus
24/04/17PRICE SENSITIVE
SUD Appendix 4C - quarterly
19/04/17PRICE SENSITIVE
SUD SUDA Completes $1.5m Capital Raising
07/04/17PRICE SENSITIVE
SUD Appendix 3B and Notice Under Section 708A
06/04/17
SUD Trading Halt
05/04/17PRICE SENSITIVE
SUD SUDA Submits Application For ArTiMist
03/04/17PRICE SENSITIVE
SUD SUDA Extends Maturity of Convertible Notes
03/04/17PRICE SENSITIVE
SUD SUDA Enters Feasibility Agreement With Pfizer
29/03/17PRICE SENSITIVE
SUD SUDA expands patent coverage for SUD-003 and SUD-004
03/03/17PRICE SENSITIVE
SUD SUDA Announces Strong Revenue For Westcoast
27/02/17PRICE SENSITIVE
SUD Half Yearly Report and Accounts
27/02/17PRICE SENSITIVE
SUD Reinstatement to official quotation
27/02/17PRICE SENSITIVE
SUD SUDA Update On Discussions with Berlin Pharma
27/02/17PRICE SENSITIVE
SUD Company Update Regarding Suspension
20/02/17
SUD SUDA receives $0.9m R&D tax incentive refund
16/02/17
SUD Company Update Regarding Suspension
10/02/17
SUD Appendix 4C - quarterly
01/02/17
SUD Suspension from official quotation
27/01/17PRICE SENSITIVE
SUD Trading Halt
24/01/17PRICE SENSITIVE
SUD BRR Audio Webcast
01/12/16
SUD Results of Meeting
25/11/16
SUD AGM presentation
25/11/16
SUD SUDA presents data on novel technology
17/11/16PRICE SENSITIVE
SUD SUDA Enters Licensing Agreement For ZolpiMist in China
09/11/16PRICE SENSITIVE
SUD Technology patent application-SUD.AX
02/11/16PRICE SENSITIVE
SUD Ceasing to be a substantial holder-SUD.AX
01/11/16
SUD Appendix 4C - quarterly-SUD.AX
31/10/16PRICE SENSITIVE
SUD Notice of Annual General Meeting/Proxy Form-SUD.AX
21/10/16
SUD Appendix 3B-SUD.AX
05/10/16
SUD Appendix 4G and Corporate Governance Statement-SUD.AX
22/09/16
SUD Annual Report to shareholders-SUD.AX
22/09/16
SUD Investor Road Show Presentation-SUD.AX
20/09/16
SUD Letter to Shareholders-SUD.AX
13/09/16
SUD Preliminary Final Report-SUD.AX
31/08/16PRICE SENSITIVE
SUD Appendix 4C - quarterly-SUD.AX
29/07/16PRICE SENSITIVE
SUD Analyst Report-SUD.AX
14/06/16
SUD Shareholder Update-SUD.AX
07/06/16
SUD Update on HC Berlin Pharma-SUD.AX
03/06/16PRICE SENSITIVE
SUD Investor presentation-SUD.AX
03/05/16
SUD Appendix 4C - quarterly-SUD.AX
29/04/16PRICE SENSITIVE
SUD Change of Director's Interest Notice-SUD.AX
28/04/16
SUD Business development update-SUD.AX
19/04/16PRICE SENSITIVE
SUD SUDA granted Canadian Patent for SUD-002-SUD.AX
12/04/16PRICE SENSITIVE
SUD Appendix 3B and Notice Under Section 708A-SUD.AX
04/04/16
SUD Appendix 3B
08/03/16
SUD Half Yearly Report and Accounts (including Appendix 4D)
26/02/16PRICE SENSITIVE
SUD SUDA Ltd investor presentation
25/02/16
SUD SUDA featured in Business Review Australia
11/02/16
SUD SUDA Ltd announces new analyst coverage
09/02/16
SUD SUDA LTD Shareholder Update
08/02/16
SUD SUDA receives $0.7m R&D tax incentive refund
05/02/16PRICE SENSITIVE
SUD Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
SUD Change of Director's Interest Notice
18/12/15
SUD Appendix 3B
18/12/15
SUD SUDA amends agreement with Amherst Pharmaceuticals
10/12/15PRICE SENSITIVE
SUD Response to Price Query Letter
07/12/15PRICE SENSITIVE
SUD Becoming a substantial holder
24/11/15
SUD Results of Meeting
17/11/15
SUD AGM Presentation
17/11/15
SUD SUDA LTD BUSINESS DEVELOPMENT UPDATE
17/11/15
SUD Ceasing to be a substantial holder
12/11/15
SUD SUDA Invited To Northern Australia Investment Forum
03/11/15
SUD Appendix 4C - quarterly
30/10/15PRICE SENSITIVE
SUD Hong Kong Presentations
29/10/15
SUD SUDA to present at Hong Kong investor showcase
26/10/15
SUD Update on 2013 Convertible Notes and Appendix 3Y
21/10/15
SUD Notice of Annual General Meeting/Proxy Form
16/10/15
SUD SUDA LTD Audio Webcast
16/10/15
SUD Letter to Shareholders
15/10/15
SUD Update on Convertible Notes and Appendix 3B
09/10/15
SUD SUDA allowed first USA patent for SUD-003 and SUD-004
08/10/15PRICE SENSITIVE
SUD SUDA releases video from Singapore investor showcase
05/10/15
SUD Annual Report to shareholders
30/09/15
SUD Appendix 4G and Corporate Governance Statement
30/09/15
SUD Appendix 3B and Notice Under Section 708A
02/09/15
SUD Preliminary Final Report
31/08/15PRICE SENSITIVE
SUD SUDA announces ArTiMist clinical publication
27/08/15PRICE SENSITIVE
SUD SUDA takes full control of ArTiMist
26/08/15PRICE SENSITIVE
SUD SUDA investor initiative and presentation
14/08/15
refresh Created with Sketch. REFRESH
 

Top Stories

HotCopper users react as Pancontinental Energy's trading halt lift reveals little

Pancontinental has lifted a trading halt to reveal its hotly awaited potential deal with Woodside is...still just potential.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024 The ASX 200 is tipped to rise as much as 1% at open today after Wall Street enjoyed another major @Trump trade” surge buoyed by year-end optimism.The Dow Jones leaped 1.06% amid the U.S. jump, with the S@P 500 following close behind with a 0.53% rise @ a trend the Aussie bou...
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.